ARTICLE
Volume 10,Issue 7
31 May 2026
Clinical Efficacy of Immunoglobulin in Infants with Bronchopulmonary Dysplasia Complicated by Respiratory Syncytial Virus Infection
Zhihui Rao ,
Qin Luo ,
Ruihua Ren ,
Jie Yu ,
Wenlin Xu ,
Qingxiong Zhu
Show Less
1
Department of Pediatric Internal Medicine, Jiangxi Provincial Maternal and Child Health Hospital( Jiangxi Provincial Women and Children’s Medical Center), Nanchang 330000, Jiangxi, China,
JCNR 2026 , 10(5), 291–298;
https://doi.org/10.26689/jcnr.v10i5.15218
© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
Objective: To investigate the clinical efficacy of immunoglobulin in infants with bronchopulmonary dysplasia (BPD) complicated by respiratory syncytial virus (RSV) infection. Methods: 104 infants with BPD complicated by RSV infection admitted to our hospital from May 2023 to November 2025 were enrolled. They were divided into observation group (n = 56, treated with immunoglobulin) and control group (n = 48, not treated with immunoglobulin), which accorded to whether they received immunoglobulin therapy. The therapeutic effects of the two groups were compared, and the levels of pulmonary function, arterial blood gas and inflammatory factors were recorded. Results: The overall therapeutic effect of the observation group was better than that of the control group (p < 0.05).The length of hospital stay and the time to disappearance of pulmonary rales were both significantly shorter in the observation group than in the control group (p < 0.05)..After treatment, the PaO2 and oxygenation index in the observation group were higher than those in the control group, while the PaCO2 was lower than that in the control group (p < 0.05).After treatment, the serum levels of CRP and WBC in the observation group were lower than those in the control group (p < 0.05). Conclusion: The immunoglobulin has a significant therapeutic effect in infants with BPD complicated by RSV infection, it can help to alleviate inflammatory response, improves pulmonary function, and possesses high clinical application value.
References
Ke Q, Qiu Y, Gan X, et al., 2023, Analysis of the Efficacy of Budesonide Combined With Pulmonary Surfactant in the Treatment of Bronchopulmonary Dysplasia in Premature Infants with a Gestational Age of < 32 Weeks. Maternal and Child Health Care of China, 38(3): 451–454.
Cortes J, Lopez-Lacort M, Mira-Iglesias A, et al., 2025, Optimal Immunization Strategy for Protection of Children < 1 Year Against Respiratory Syncytial Virus Infection and Hospitalization. Bulletin of Mathematical Biology, 88(1): 9.
Li G, Huang Y, Fan Y, et al., 2025, Clinical Characteristics and Prognosis of Lower Respiratory Tract Infections in Infants with Bronchopulmonary Dysplasia. Chongqing Medical Journal, 54(2): 366–371.
Li J, Zhong P, Liao Y, et al., 2025, Survey on Knowledge, Attitudes, and Behaviors Related to the Prevention and Treatment of Respiratory Syncytial Virus Infection Among Caregivers of Children Aged 0–12 Months in Shanghai in 2024. Chinese Journal of Vaccines and Immunization, 31(3): 336–341.
Pediatric Professional Committee of China Medical Education Association, Respiratory Group of Pediatric Branch of Chinese Medical Association, Neonatology Group of Pediatric Branch of Chinese Medical Association, et al., 2022, Expert Consensus on the Management of Bronchopulmonary Dysplasia in Children. Chinese Journal of Practical Pediatrics, 37(20): 1527–1538.
National Clinical Research Center for Child Health and Diseases, Infectious Disease Group of Pediatric Branch of Chinese Medical Association, Infectious Disease Branch of Shanghai Medical Association, et al., 2024, Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Respiratory Syncytial Virus Infection in Children (2023 Edition). Journal of Clinical Pediatrics, 42(1): 1–14.
Mariani A, Ghezzi E, Pesenti N, et al., 2025, Nasal High-Flow Therapy Versus Low-Flow Oxygen Therapy Post-Discharge in Infants with Bronchopulmonary Dysplasia: A Retrospective Observational Study. Pediatric Pulmonology, 60(1): e27450.
Yu B, Gong C, He P, 2023, Correlation of Serum 25-Hydroxyvitamin D and Immunoglobulin Levels With the Occurrence and Severity of Pneumonia in Infants and Young Children. Journal of Molecular Diagnostics and Therapy, 15(2): 310–313.
Deng J, Yu L, 2025, Preparation and Application of a Human-Mouse Chimeric Respiratory Syncytial Virus-Immunoglobulin M Recombinant Antibody. Journal of Xinxiang Medical University, 42(7): 538–543.
Dong H, Feng L, Shi S, et al., 2025, Efficacy of Recombinant Human Interferon Combined with Human Immunoglobulin in the Treatment of Children with Severe RSV Pneumonia. Chinese Journal of Drug Application and Monitoring, 22(7): 1273–1277.
Zeng L, Xie X, Chen X, et al., 2020, Clinical Characteristics and Pathogen Analysis of Readmission for Lower Respiratory Tract Infections Within 2 Years in Children with Bronchopulmonary Dysplasia (With a Report of 52 Cases). Chinese Journal of Practical Pediatrics, 35(11): 885–890.
Yu Y, Zhou P, Wu Y, et al., 2026, Expert Consensus on the Prevention of Respiratory Syncytial Virus Infection in Infants and Young Children with Special Health Conditions. Chinese Journal of Perinatal Medicine, 29(2): 105–116.
Yang S, Qi X, Chen J, et al., 2022, Clinical Efficacy of Human Immunoglobulin in the Treatment of Children with Infectious Pneumonia and Its Impact on Serum-Related Factor Levels. Maternal and Child Health Care of China, 37(9): 1635–1638.
Mohamed B, Kulkarni A, Duffy D, et al., 2025, Respiratory Physiological Changes Post Initiation of Neurally Adjusted Ventilatory Assist in Preterm Infants with Evolving or Established Bronchopulmonary Dysplasia. European Journal of Pediatrics, 184(2): 159.
Lv M, Chen Q, Pang Y, et al., 2022, Clinical Value of Detecting Serum Cysteinyl Leukotrienes, Eosinophil Cationic Protein, Immunoglobulin E, and Serum Inflammatory Factors in Children with Bronchiolitis Caused by Respiratory Syncytial Virus Infection. Anhui Medical and Pharmaceutical Journal, 26(2): 365–368.
Cai S, Zhu C, Chen F, et al., 2023, Construction of a Risk Model for Severe Adenovirus Pneumonia in Children and a Prospective Study on the Timing of Intravenous Immunoglobulin Treatment. Chinese Journal of Contemporary Pediatrics, 25(6): 619–625.
Liu S, Zhang Y, Zhao X, 2024, Mechanism of microRNA-93-5p in Regulating the Toll-Like Receptor 4 Gene to Inhibit the Inflammatory Response of Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus. Chinese Journal of Virology, 40(3): 469–475.
Santos L, Antunes K, Muraro S, et al., 2021, TNF-Mediated Alveolar Macrophage Necroptosis Drives Disease Pathogenesis During Respiratory Syncytial Virus Infection. European Respiratory Journal, 57(6): 2003764.
Zhang L, Zhong X, 2023, Effects and Significance of Overweight/Obesity Factors on Serum Immunoglobulin and IGF-1 Levels in Children with Recurrent Respiratory Tract Infections. Journal of Public Health and Preventive Medicine, 34(2): 139–142.
Ding Y, Zhang H, Xianyu X, 2025, Efficacy of Budesonide Aerosol Inhalation Combined with Intravenous Immunoglobulin in the Treatment of Children with Infectious Pneumonia and Its Impact on Inflammatory Marker Levels. Northwestern Pharmaceutical Journal, 40(6): 179–185
Share
Back to top
Bio-Byword Scientific Publishing Pty. Ltd.
We are committed to supporting the scientific community by publishing impactful research and fostering effective communication among scientists. We continuously seek ways to accelerate scientific progress while upholding transparency and open dialogue. Our goal is to make knowledge freely and barrier‑free accessible to all.
Contact us: info@bbwpublisher.com
Level 10, 50 Clarence Street Sydney, NSW 2000 Australia